Meropenem and Sodium Chloride
Brand Names: Meropenem and Sodium Chloride Generic
Methodology & AI Transparency ⓘ
Meropenem and Sodium Chloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed penem antibacterial (0264-3183, 0264-3185, manufactured/labeled by B.
- 2 Real-world patient consensus: Zero-PHI community consensus: 93% favorable across 8 logged regimens (Meropenem and Sodium Chloride Generic).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $5.6550).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Meropenem and Sodium Chloride include diarrhea (8.3%), nausea (8.3%), headache (6.5%).
Ask our AI Specialists anything about Meropenem and Sodium Chloride
Meropenem and Sodium Chloride Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed penem antibacterial (0264-3183, 0264-3185, manufactured/labeled by B. Braun Medical Inc.), Meropenem and Sodium Chloride provides intravenous-route dosing across 500 mg/50mL Injection, Solution and 1 g/50mL Injection, Solution under licensed medical supervision.
Acting as a intravenous-route penem antibacterial moiety, Meropenem and Sodium Chloride (NDC 0264-3183, 0264-3185, manufactured/labeled by B. Braun Medical Inc.) regulates downstream signaling pathways proportional to 500 mg/50mL Injection, Solution and 1 g/50mL Injection, Solution titration and patient renal/hepatic reserve.
Clinical clearance of Meropenem and Sodium Chloride (Penem Antibacterial) relies on dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of meropenem and sodium chloride with a Mean elimination half-life of 4 to 15 hours across adult Meropenem and Sodium Chloride dosing half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Meropenem and Sodium Chloride (500 mg/50mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after meropenem and sodium chloride administration.
FDA clinical labeling for Meropenem and Sodium Chloride restricts administration in contraindicated in patients with prior serious allergic response to meropenem and sodium chloride (ndc 0264-3183); severe baseline organ impairment where meropenem and sodium chloride accumulation exceeds safe therapeutic margins across 500 mg/50mL Injection, Solution, 1 g/50mL Injection, Solution, with self-reported patient tracking dominated by nausea (8.3% of reports), diarrhea (8.3% of reports), headache (6.5% of reports).
Reconcile eGFR-adjusted medications before escalating Meropenem and Sodium Chloride in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Meropenem and Sodium Chloride dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Meropenem and Sodium Chloride (NDC 0264-3183)
- Severe baseline organ impairment where Meropenem and Sodium Chloride accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (8 Reports)
Meropenem and Sodium Chloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Meropenem and Sodium Chloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on A phase III, multicenter, gold-standard blind, randomized clinical trial to In Chinese adult participants with cIAI, C/T plus metronidazole was noninferior to meropenem, with comparable safety. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35987467 ↗ |
| Can This Approach Help? Inside the Latest Research on Outcomes in participants with failure of initial antibacterial therapy for This post hoc analysis further supports the previously demonstrated lower ACM rate for ceftolozane/tazobactam versus meropenem among participants who were failing prior therapy, despite the lack of significant differences in... Critical care (London, England) • 2022-12-01 • Phase III Randomized Trial | N = 53 | 88/100 | PMID 36457059 ↗ |
| Can This Approach Help? Inside the Latest Research on Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa Among participants with emergence of nonsusceptibility to meropenem, clinical outcomes were similar to overall clinical outcomes in the ASPECT-NP meropenem arm. International journal of antimicrobial agents • 2021-03-15 • Phase III Randomized Trial | N = 59 | 88/100 | PMID 33434676 ↗ |
| New Insights on Pooled data from phase 3 clinical trials comparing the clinical activity of: What a 721-Participant Study Found The efficacy of C/T plus metronidazole was comparable with meropenem even for cIAIs and C/T plus metronidazole might be an alternative treatment option for cIAI. Infectious diseases (London, England) • 2026-01-15 • Phase III Randomized Trial | N = 721 | 87/100 | PMID 40913503 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients We determined if the results for the Indian patients were in-line with the results of overall population. Indian journal of medical microbiology • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34045081 ↗ |
Meropenem and Sodium Chloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5.6550/unit (~$169.65/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Meropenem and Sodium Chloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Meropenem and Sodium Chloride RxNorm Concept ID | RXN-02643183-2545 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5.6550 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Meropenem and Sodium Chloride Patient Community, Cohort Filters & Dosage Logs
Deterministic Meropenem and Sodium Chloride reference combining NIH RxNorm (RXN-02643183-2545), Medicaid NADAC ($5.6550/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Meropenem and Sodium Chloride community threads and patient logs by age, biological sex, dosage, and treatment duration.